India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
20/08/2026 09:09
BUZZ-India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray ** Pharmaceutical company Glenmark Pharma's shares GLEN.NS rise as much as 3.54%, the biggest single-session jump in three weeks, to 2326 rupees apiece
** Rise after GLEN announces the receipt of U.S. drug regulator's approval for nasal spray, Fluticasone Propionate, therapeutically equivalent to the drug Flonase nasal spray, used to treat hay fever, nasal congestion
** According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal spray market achieved annual sales of $295.2 million
** GLEN shares are up 13.5% in 2026 so far, almost mirroring the 16.2% rise in pharma index .NIPHARM, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter